About S-Cubed Capital
S-Cubed Capital is a venture capital firm founded in 2012. It is primarily based out of Menlo Park, United States. As of Jun 2025, S-Cubed Capital is an active investor, having invested in 15 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from High Tech to Life Sciences and Consumer. Most recently it participated in the $***** Series C round of Antheia Overall, S-Cubed Capital portfolio has seen 1 IPO and 7 acquisitions including key companies like Innovium, Pliant and Decibel Therapeutics. A lot of funds co-invest with S-Cubed Capital, with names like Menlo Ventures sharing a substantial percentage of its portfolio. S-Cubed Capital has team of 6 people.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
S-Cubed Capital's List of Top Investments
S-Cubed Capital has a portfolio of 15 companies. Their most notable investments are in Future Finance and Mira.Their portfolio spans across United States and Ireland. They have invested in High Tech, Life Sciences, Consumer and 12 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by S-Cubed Capital:1. Antheia
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Key facts about Antheia
- Founded Year: 2013
- Location: Palo Alto (United States)
- Stage: Series C
- Total Funding till date: $176M
- Employee Count: 65 as on Mar 31, 2026
- Investors: Viking Global Investors, SVB and 15 Others
- Latest Funding Round: Series C, Jan 27, 2026, $*****
- Highlight: Editors' Pick
2. Innovium
Innovium is a venture-funded company developing semiconductor solutions to address the biggest networking challenges facing data centers. It was founded by leading industry veterans from Broadcom and Cavium. It has received significant funding from marque investors in Silicon Valley. In March 2017, it launched its TeraLynx chip with a 12.8 Tbit/s switch on a single 16nm die. This was significantly better than Broadcom's Ethernet switch where it is a major player.
Key facts about Innovium
- Founded Year: 2014
- Location: San Jose (United States)
- Stage: Acquired
- Total Funding till date: $350M
- Employee Count: 75 as on Oct 31, 2021
- Investors: BlackRock, DFJ Growth and 11 Others
- Latest Funding Round: Series E, Jul 21, 2020, $*****
- Highlight: Acquired
3. Pliant
Developer of drugs related to Fibrosis, COVID-19, and Muscular Dystrophies. Its one of the product in the pipeline is PLN-74809 that is an oral, small molecule, a dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and COVID-19 related ARDS. Another product PLN-1474 is for NASH-Associated Liver Fibrosis.
Key facts about Pliant
- Founded Year: 2016
- Location: Redwood City (United States)
- Annual Revenue: $1.58M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $207M
- Employee Count: 158 as on Dec 31, 2023
- Investors: HTIF, Redmile Group and 12 Others
- Latest Funding Round: Series C, Mar 03, 2020, $*****
- Highlight: Public
Decibel Therapeutics is a developer of new medicines to protect, repair, and restore hearing capacity. It is an early stage biotechnology company developing drugs that can be directly injected into the inner ear. They have multiple modalities – with candidates being developed in the antibody, small molecule and siRNA spaces. It focused broadly across hearing disorders, including patients who commonly experience ototoxicity, or hearing loss as a side effect of different treatments; noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants, and others.
Key facts about Decibel Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Stage: Acquired
- Total Funding till date: $170M
- Employee Count: 9 as on Mar 31, 2026
- Investors: Janus Henderson Investors, Orbimed and 16 Others
- Latest Funding Round: Series D, Nov 09, 2020, $*****
- Highlight: Acquired
5. Exactuals
Cloud-based payroll management system for enterprises. Its offers products include secure payee registration, payment calculation, and execution, rich reporting, encrypted payments, etc. It also offers a centralized self-service portal for employees. Sectors serviced are music, film, TV, marketplaces, and corporates.
Key facts about Exactuals
- Founded Year: 2011
- Location: Los Angeles (United States)
- Stage: Acquired
- Total Funding till date: $20.6M
- Employee Count: 23 as on Mar 31, 2026
- Investors: TTV Capital, Palo Alto Venture Partners and 12 Others
- Latest Funding Round: Series B, Feb 15, 2017, $*****
- Highlight: Acquired
S-Cubed Capital's Year-on-Year Investment Trends
S-Cubed Capital has invested in 15 companies over the last 14 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in Antheia and most recent follow-on round was in Innovium.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 |
2020 | 1 | 2 | 3 |
2019 | 0 | 1 | 1 |
2018 | 1 | 2 | 3 |
2017 | 3 | 1 | 4 |
S-Cubed Capital's Investments by Stage
S-Cubed Capital has made 5 investments in Series A stage with an average round size of $9.37M, 4 investments in Seed stage with an average round size of $2.45M, 2 investments in Series C stage with an average round size of $42.8M, 1 investment in Series B stage with an average round size of $62M and 1 investment in Series D stage with an average round size of $82.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Seed | 4 |
Series C | 2 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
S-Cubed Capital's Investments by Sector
S-Cubed Capital has a diverse portfolio, with companies operating in the High Tech, Life Sciences, Consumer, Enterprise Applications and FinTech. Notably, it has invested in 15 Tech companies, 9 Enterprise (B2B) companies, 7 Software companies and at least 6 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
High Tech | 4 |
Life Sciences | 4 |
Consumer | 3 |
Enterprise Applications | 3 |
FinTech | 2 |
Others | 15 |
Note: We have considered here, only first round of investments
S-Cubed Capital's Investments by Geography
S-Cubed Capital has made most investments in United States (12), followed by Ireland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 12 |
Ireland | 1 |
Note: We have considered here, only first round of investments
S-Cubed Capital's recent investments
S-Cubed Capital has not made any investment in 2026 so far.Here are the most recent investments by S-Cubed Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 03, 2025 | United States | Series C | 9574 | ||
Nov 09, 2020 | United States | Series D | 9809 | [+9] | |
Jul 21, 2020 | United States | Series E | 4462 | [+8] | |
Mar 03, 2020 | United States | Series C | 6817 | ||
Jun 26, 2019 | Ireland | Series C | 3922 | - |
IPOs and Publicly Listed companies in S-Cubed Capital's Portfolio
1 of S-Cubed Capital's portfolio company became public - Pliant. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2020 at marketcap of $547MHere are S-Cubed Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 03, 2020 | Jul 16, 2018 | Series B | 9325 |
Acquired companies in S-Cubed Capital's Portfolio
7 companies from S-Cubed Capital's portfolio have been acquired. The most recent acquisition was Decibel Therapeutics in Aug 2023 by Regeneron Pharmaceuticals for $*****.Here are S-Cubed Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 10, 2023 | Nov 09, 2020 | Series D | 6324 | |
Jun 07, 2023 | Jul 18, 2017 | Seed | 2386 | |
Aug 03, 2021 | Jan 2015 | Series A | 9723 | |
Mar 16, 2021 | Oct 12, 2012 | Seed | 9446 | |
Aug 13, 2018 | Feb 08, 2017 | Series A | 1540 |
Team profile of S-Cubed Capital
S-Cubed Capital has a team of 6 members including 2 Principals located in United States. S-Cubed Capital's team does not sit on the board of any company as of now.Co-investors of S-Cubed Capital
Over the past 14 years, 124 investors have co-invested in S-Cubed Capital's portfolio companies. This includes funds and angels.
- Invested before S-Cubed Capital: Third Rock Ventures, Viking Global Investors and 26 others have invested in rounds before S-Cubed Capital. There are 2 companies where Third Rock Ventures has invested before S-Cubed Capital and 1 company where Viking Global Investors has invested before S-Cubed Capital.
- Top Co-investors of S-Cubed Capital: 60 investors entered a company along with S-Cubed Capital. These include investors like Menlo Ventures (2 companies).
- Invested after S-Cubed Capital: A total of 36 investors have invested in S-Cubed Capital's portfolio after their investments. Top Investors include Greylock Partners (2 companies), AFF (1 company) and Redline Capital Management (1 company).
Recent News related to S-Cubed Capital
•
Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategyintelligence360•Jun 16, 2025•SG Growth Capital, Global Health Investment, Singapore Economic Development Board, S-Cubed Capital and 6 others
•
Antheia Scores $56 Million Series Csvdaily.com•Jun 06, 2025•Antheia, Global Health Investment, EDBI, Athos Capital and 5 others
•
Breakout Ventures closes of USD112.5m Fund IIPrivate Equity Wire•Dec 10, 2021•Breakout Ventures, Dolby Family Ventures, Thiel Foundation, GRIDS Capital and 3 others
•
Innovium Secures $170M in New Funding to Accelerate Product and Customer Momentum WorldwideBusiness Wire•Jul 21, 2020•Innovium, DFJ Growth, BlackRock, Greylock Partners and 10 others
•
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic ...Pliant•Mar 03, 2020•Pliant, Novartis, Redmile Group, Farallon Capital Management and 9 others
•
Notion Capital collects over $150 mln for fourth fundPE Hub•Oct 03, 2019•Notion, Play.com, British Patient Capital, S-Cubed Capital and 11 others
•
•
RBC's City National buys entertainment industry payments tech firmSeeking Alpha•Aug 13, 2018•City National Bank, Exactuals, TTV Capital, StartX and 9 others
•
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic DiseasesPR Newswire•Jul 16, 2018•Pliant, Cowen, Eventide Asset Management, Schroder Adveq and 4 others
•
Innovium Closes $77M in Series D Funding to Drive Commercial Volume Ramps and Innovative Product RoadmapsBusiness Wire•Apr 25, 2018•Innovium, Greylock Partners, Walden International, Qualcomm Ventures and 5 others
